AveXis and Its Potential ALS Gene Therapy to Be Purchased by Novartis for $8.7B
News
AveXis, which is running clinical trials of a promising gene therapy for spinal muscular atrophy (SMA) — and developing a potentially similar therapy for a genetic form of amyotrophic lateral sclerosis ... Read more